Drug Approval (Additional Indication)
AstraZeneca Receives CDSCO Approval for Expanded Use of Calquence in India
NSE
astrazen
BSE
506820
AstraZeneca Pharma India Limited has received regulatory approval from CDSCO to import and market Calquence (Acalabrutinib) 100 mg tablets in India for an additional indication in blood cancer treatment. This expands the drug’s usage in chronic lymphocytic leukemia (CLL).
PRICE-SENSITIVE TRIGGER
Event: Regulatory Approval
Type: Drug Approval (Additional Indication)
Impact: Positive
Immediate Effect: Expands product usage and potential revenue stream
Key Metrics
- Drug: Acalabrutinib (Brand: Calquence)
- Dosage: 100 mg Tablets
- Approval Type: Additional Indication
- Therapy Area: Blood Cancer (CLL / SLL)
Highlights
Expanded indication approval for key oncology drug
What Happened ?
AstraZeneca Pharma India Limited announced that it has received approval from the Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of Acalabrutinib tablets (Calquence) for an additional indication.
The approval allows the drug to be used in combination therapies for treating previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Details Breakdown
Approval Details
- Approval granted by CDSCO (India’s drug regulator)
- Covers additional therapeutic indication
- Applicable for combination treatment use
Treatment Scope
- Indicated for CLL (Chronic Lymphocytic Leukemia)
- Also applicable for SLL (Small Lymphocytic Lymphoma)
- Used in combination with venetoclax ± obinutuzumab
Business Significance
- Expands market potential of Calquence in India
- Strengthens AstraZeneca’s oncology portfolio
- Enhances revenue opportunities in specialty pharma
Risk Analysis
Key Risks
- Regulatory and compliance dependencies
- Market adoption and physician acceptance
- Pricing and competition in oncology segment
Worst Case Scenario
Limited adoption or pricing pressure could restrict expected revenue benefits
Risk Level: Medium
Company Commentary
- Approval enables marketing of Calquence for expanded indication
- Subject to additional statutory approvals if required
- Strengthens oncology treatment offerings in India
Official Exchange Filing: AstraZeneca Pharma India Limited